As I’ve reported, USV-backer UTIMCO disclosed in a recent filing that USV had delivered the public investment fund an internal rate of return of 59%. And that number will likely go up over time. (For instance, USV portfolio company Casetext sold to Thomson Reuters for $650 million after the UTIMCO performance update.)
I invited USV partner Rebecca Kaden onto the Newcomer podcast to talk about how USV consistently invests in unconventional companies.
We started off our conversation talking about Journey Clinical, the psychedelics company, in which Kaden announced a Series A investment in January.
We also discussed USV’s $200 million climate fund strategy, her interest in the AI application layer, and how rising interest rates are affecting the venture capital asset class.